Pharma Journalist -

Ligand Pharmaceuticals Incorporated announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections,…
Read More...

Xencor announced that the first patient has been dosed in XmAb23104-01 (DUET-3), a Phase 1 clinical study to evaluate the safety and tolerability of XmAb23104, a bispecific antibody…
Read More...

On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused…
Read More...

Skyhawk Therapeutics announced a strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) in which Skyhawk will use its SkySTAR technology platform to discover and…
Read More...

The U.S. Food and Drug Administration approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.…
Read More...

Samsung BioLogics and GI Innovation signed a Contract Development Organization (CDO) contract for immunochemotherapy at Samsung BioLogics headquarters on Thursday. GI Innovation…
Read More...

Sartorius Stedim Biotech (SSB) is introducing its new generation of ambr 15 cell culture automated microbioreactor system. The Generation 2 is the successor to the well-established ambr…
Read More...

AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, announces that it has entered into a collaborative agreement with Boehringer…
Read More...

Amgen and Syapse announced a precision medicine collaboration in oncology. Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess…
Read More...

Takeda Pharmaceutical Company Limited announced the opening of a new research facility in San Diego, California. Extending Takeda’s 14-year presence in San Diego, the…
Read More...